Janssen Presents Updated Results Evaluating First-in-Class T

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the MonumenTAL-1 Phase 1 first-in-human...

Related Keywords

California , United States , American , Namita Krishnan , Obrian Kenney , Sen Zhuang , Jessica Moore , Janssen Biotech Inc , American Society Of Hematology Annual Meeting , Janssen Research Development , Janssen Pharmaceutical Companies , Janssen Pharmaceutical Companies Of Johnson , American Society Of Hematology , Receptor Familyc Group , Clinical Research , Department Of Hematology , American Cancer Society , None Of The Janssen Pharmaceutical Companies , Other Administration Reactions , European Commission , Division Of Multiple Myeloma , Exchange Commission , Companies Of Johnson , Amgen Inc , Johnson , City Of Hope Comprehensive Cancer Center , American Society , Multiple Myeloma , Hematopoietic Cell Transplantation , Hope Comprehensive Cancer Center , Vice President , Janssen Research , Evaluating Talquetamab , Part One , Janssen Biotech , Mayo Stage , Plight Chain , Indirect Antiglobulin Test , Indirect Coombs , Pharmaceutical Companies , Infectious Diseases , Private Securities Litigation Reform Act , Annual Report , Note Regarding Forward Looking , Quarterly Report , First In Human Study , Refractory Multiple , Hematology Annual , Subcutaneous Talquetamab Plus Daratumumab , Patients With , Natl Acad Sci United , Accessed October , Statistics About Multiple Myeloma , Janssen ,